background
pattern
corticosteroid
usag
sever
acut
respiratori
syndrom
sar
associ
treatment
outcom
hong
kong
studi
method
patient
year
old
either
receiv
corticosteroid
taken
corticosteroid
within
day
symptom
onset
includ
patient
receiv
corticosteroid
beyond
day
investig
treatment
within
day
symptom
onset
exclud
elig
patient
major
corticosteroid
dosagetyp
combin
analys
result
crude
death
rate
lower
among
steroidtr
patient
compar
patient
group
steroid
vs
among
four
corticosteroid
group
studi
mortal
lowest
lowdos
oral
prednisolon
group
p
highdos
methylprednisolon
group
mp
group
multivari
analysi
corticosteroid
group
independ
factor
relat
death
corticosteroid
group
older
age
comorbid
wors
chest
xray
score
wors
respiratori
statu
day
higher
admiss
white
cell
count
group
p
mp
significantli
lower
adjust
odd
ratio
death
lower
bacteri
fungal
cultur
rate
despit
wors
chest
xray
score
higher
cumul
corticosteroid
dosag
group
mp
compar
group
p
fewer
patient
requir
rescu
puls
corticosteroid
patient
hydrocortison
group
hc
highest
posit
cultur
rate
specul
corticosteroid
higher
invitro
inflammatori
potenc
administ
time
dosag
commensur
diseas
sever
may
conduc
better
outcom
sar
consequ
effect
control
immunopatholog
lung
damag
role
corticosteroid
treatment
sever
acut
respiratori
syndrom
sar
controversi
hong
kong
corticosteroid
wide
use
report
efficaci
mainland
china
four
five
initi
sar
patient
die
best
support
treatment
alon
without
corticosteroid
surviv
rate
hong
kong
improv
combin
corticosteroid
ribavirin
treatment
subsequ
patient
methylprednisolon
puls
dosag
mg
per
dose
also
frequent
ad
baselin
corticosteroid
regimen
deterior
recrudesc
symptom
sign
sar
propos
triphas
diseas
commenc
viral
replic
follow
immunopatholog
damag
final
pulmonari
destruct
advoc
corticosteroid
aim
control
immunopatholog
phase
sar
suppress
elev
cytokin
level
oppon
contend
selflimit
cours
observ
sar
even
signific
initi
chest
radiograph
involv
corticosteroid
increas
suscept
secondari
infect
hong
kong
hospit
author
sar
collabor
group
hascog
track
inform
probabl
confirm
hong
kong
sar
patient
defin
world
health
organis
criteria
follow
studi
aim
studi
pattern
corticosteroid
usag
associ
treatment
outcom
clinic
inform
sar
patient
retrospect
collect
may
octob
enhanc
ha
clinic
manag
system
cm
provid
onlin
laboratori
medic
inform
follow
patient
includ
year
age
still
hospitalis
sar
march
discoveri
novel
coronaviru
cov
announc
hong
kong
either
ii
given
corticosteroid
throughout
cours
hospitalis
iii
receiv
corticosteroid
within
day
symptom
onset
includ
patient
fulfil
latest
case
definit
sar
patient
exclud
discharg
die
march
lack
knowledg
result
variat
manag
ii
corticosteroid
start
beyond
day
symptom
onset
iii
receiv
investig
treatment
within
day
symptom
onset
includ
lopinavirritonavir
combin
immunoglobulin
convalesc
plasma
antitumour
necrosi
factora
tradit
chines
medicin
demograph
data
serial
laboratori
test
result
intens
care
unit
admiss
requir
puls
methylprednisolon
rescu
assist
ventil
microbiolog
find
includ
bacteri
viral
fungal
cultur
antibiot
usag
final
outcom
record
presenc
comorbid
defin
ill
possibl
advers
impact
patient
outcom
name
diabet
document
endorgan
complic
vascular
cardiac
neurolog
renal
ii
chronic
obstruct
pulmonari
diseas
exclud
chronic
asthma
iii
chronic
diseas
requir
longterm
treatment
cardiac
pulmonari
neurolog
renal
liver
laboratori
variat
refer
rang
lactat
dehydrogenas
ldh
ldh
ratio
obtain
divid
measur
valu
respect
upper
limit
normal
rang
use
comparison
posit
cultur
microorgan
includ
bacteria
fungi
document
posit
laboratori
confirm
sarscov
infect
defin
two
posit
realtim
revers
transcriptaseepolymeras
chain
reaction
rtepcr
sarscov
nasopharyng
aspir
nasopharyng
swab
stool
posit
rtepcr
one
specimen
confirm
two
laboratori
fourfold
rise
igg
sarscov
pair
acuteconvalesc
sera
fourfold
threshold
igg
singl
sera
criteria
identifi
laboratoryconfirm
case
adopt
studi
effect
initi
dosag
subsequ
diseas
cours
predomin
type
corticosteroid
employ
defin
contribut
least
twothird
total
dosag
first
four
day
treatment
exclud
dosag
due
puls
mp
rescu
subsequ
analysi
base
follow
corticosteroid
type
intraven
hydrocortison
group
hc
intraven
methylprednisolon
group
mp
oral
prednisolon
group
p
intraven
puls
corticosteroid
group
puls
puls
corticosteroid
defin
intraven
methylprednisolon
administ
mg
per
dose
least
day
day
corticosteroid
commenc
rescu
puls
defin
intraven
methylprednisolon
administ
mg
per
dose
least
day
start
least
day
corticosteroid
treatment
patient
receiv
corticosteroid
design
group
steroid
within
patient
receiv
ribavirin
identifi
patient
major
type
corticosteroid
exclud
analys
defin
receiv
one
type
corticosteroid
exclud
puls
methylprednisolon
total
dosag
type
reach
least
twothird
total
corticosteroid
dosag
first
day
steroid
commenc
reflect
antiinflammatori
effect
steroid
type
convert
hydrocortisoneequival
base
rel
glucocorticoid
activ
follow
ratio
mg
methylprednisolon
mg
prednisolon
mg
hydrocortison
chest
radiograph
score
use
score
system
indic
geograph
extent
radiograph
opac
score
total
score
rang
six
lung
zone
lowermiddleupp
left
right
lung
higher
score
denot
extens
chest
xray
cxr
involv
score
method
standardis
perform
radiologist
individu
hospit
pao
fio
pf
ratio
defin
studi
worst
arteri
partial
pressur
oxygen
pao
divid
fraction
inspir
oxygen
concentr
fio
particular
day
use
reflect
patient
respiratori
statu
pao
valu
avail
estim
oxygen
satur
valu
obtain
puls
oximetri
spo
use
oxygen
dissoci
curv
help
equat
relat
spo
pao
standard
temperatur
c
respiratori
statu
categoris
accord
worst
pf
ratio
day
kpa
mmhg
acut
respiratori
distress
syndrom
ard
kpa
mmhg
acut
lung
injuri
ali
higher
valu
arbitrarili
divid
mild
respiratori
impair
ri
kpa
mmhg
normal
kpa
mmhg
sinc
sarsrel
acut
respiratori
failur
arf
usual
peak
day
symptom
onset
patient
outcom
studi
accord
respiratori
statu
day
symptom
onset
outcom
primari
outcom
studi
surviv
benefit
differ
treatment
group
studi
potenti
lifethreaten
infecti
complic
corticosteroid
possibl
impact
outcom
result
bacteri
fungal
cultur
togeth
treatment
fungal
infect
tuberculosi
record
secondari
outcom
sinc
ribavirin
use
sar
patient
studi
final
analysi
perform
patient
ever
receiv
ribavirin
order
remov
confound
effect
ribavirin
ethic
committe
approv
consid
necessari
direct
patient
intervent
involv
individu
patient
data
present
data
present
mean
ae
sd
median
interquartil
rang
iqr
twosid
kruskalew
test
chisquar
test
use
univari
comparison
demograph
clinic
paramet
among
group
appropri
multivari
logist
regress
analys
perform
backward
select
variabl
show
p
valu
univari
analysi
wilcoxon
test
normal
approxim
chisquar
test
predict
effect
variou
corticosteroid
group
surviv
adjust
possibl
confound
factor
select
model
gave
adjust
ratio
odd
death
confid
interv
individu
corticosteroid
group
rel
chosen
refer
group
control
identifi
confound
factor
use
demograph
variabl
clinic
paramet
admiss
model
entri
first
multivari
model
studi
surviv
outcom
variou
corticosteroid
group
group
steroid
analys
perform
use
clinic
paramet
steroid
commenc
rather
admiss
compar
among
steroid
group
surviv
rate
model
corticosteroid
group
show
highest
surviv
benefit
group
steroid
first
multivari
model
select
refer
group
analys
p
valu
consid
statist
signific
statist
analys
done
use
sa
version
outbreak
hong
kong
total
probabl
sar
patient
criteria
treat
acut
gener
hospit
ha
per
defin
exclus
criteria
patient
exclud
reason
shown
tabl
result
final
cohort
major
corticosteroid
group
consist
patient
demograph
clinic
paramet
patient
acut
hospit
hong
kong
shown
tabl
major
patient
total
receiv
corticosteroid
two
hospit
use
centrespecif
treatment
protocol
patient
throughout
outbreak
dosag
type
corticosteroid
use
clearli
defin
hospit
utilis
two
corticosteroid
regimen
patient
group
base
commonest
corticosteroid
type
use
patient
order
frequenc
follow
hydrocortison
group
hc
methylprednisolon
group
mp
puls
methylprednisolon
group
puls
prednisolon
group
p
patient
receiv
steroid
group
steroid
distribut
hospit
stepdown
strategi
corticosteroid
dosag
observ
steroid
treatment
group
unless
deterior
occur
call
use
puls
methylprednisolon
rescu
detail
individu
patient
group
steriod
retriev
knowledg
patient
minor
diseas
diagnos
discharg
particular
earli
part
outbreak
viru
identifi
diagnost
test
develop
present
late
cours
outbreak
atyp
symptom
diarrhoea
physician
believ
administ
corticosteroid
unknown
diseas
baselin
characterist
clinic
paramet
admiss
statist
differ
among
group
tabl
particular
group
p
consist
youngest
patient
largest
number
health
care
worker
mildest
diseas
admiss
evidenc
lowest
median
cxr
score
normal
respiratori
statu
absenc
ard
group
mp
highest
median
cxr
score
admiss
two
group
highest
preval
ard
admiss
group
puls
steroid
respect
also
highest
mortal
rate
respect
overal
crude
death
rate
lowest
group
p
group
mp
tabl
show
detail
patient
receiv
corticosteroid
tabl
show
gener
characterist
significantli
differ
amongst
group
steroid
commenc
earliest
group
hc
latest
group
puls
median
day
iqr
iqr
respect
symptom
onset
among
group
group
mp
lowest
proport
patient
requir
puls
corticosteroid
rescu
compar
group
also
given
latest
time
point
median
day
symptom
onset
compar
day
group
total
cumul
corticosteroid
dosag
highest
group
puls
durat
steroid
treatment
shortest
group
p
median
day
longest
group
mp
median
day
latter
dictat
protocol
tabl
show
patient
clinic
paramet
corticosteroid
commenc
group
p
still
mildest
diseas
compar
group
mp
group
puls
worst
clinic
statu
evidenc
highest
percentag
patient
ard
respect
highest
median
cxr
score
iqr
iqr
respect
tabl
show
clinic
paramet
puls
corticosteroid
commenc
group
p
consist
mildest
diseas
lowest
median
cxr
score
patient
either
ali
ard
contrast
patient
group
mp
worst
clinic
statu
highest
median
cxr
score
either
ali
ard
remov
possibl
confound
effect
due
ribavirin
patient
treat
ribavirin
group
steroid
group
hc
group
mp
group
p
group
puls
exclud
analys
final
outcom
among
patient
group
steroid
comparison
patient
receiv
ribavirin
univari
analysi
fail
show
signific
differ
demograph
characterist
includ
comorbid
percentag
laboratori
confirm
percentag
health
care
worker
admiss
paramet
respiratori
statu
white
cell
count
neutrophil
ldh
cxr
score
well
major
outcom
data
shown
univari
comparison
characterist
survivor
fatal
case
among
patient
tabl
indic
age
sex
comorbid
worst
respiratori
statu
day
worst
xray
score
ldh
ratio
wbc
neutrophil
count
admiss
corticosteroid
treatment
reach
statist
signific
p
patient
complet
data
multivari
analysi
aggreg
effect
corticosteroid
usag
compar
group
steroid
surviv
insignific
control
age
sex
comorbid
highest
cxr
score
worst
respiratori
statu
day
wbc
admiss
fig
show
group
p
lowest
percentag
survivor
posit
bacteri
cultur
throughout
hospitalis
group
mp
receiv
highest
total
dosag
corticosteroid
tabl
show
slightli
higher
rate
day
group
also
highest
surviv
rate
group
hc
steroid
puls
compar
higher
cultur
rate
day
higher
mortal
rate
group
hc
highest
posit
cultur
antifung
treatment
rate
group
p
mp
similar
low
rate
new
case
tuberculosi
uncommon
rate
highest
group
hc
present
studi
largest
comprehens
review
date
use
corticosteroid
sar
treatment
multivari
analysi
corticosteroid
use
whole
show
surviv
benefit
compar
steroid
use
howev
individu
corticosteroid
type
analys
group
mp
intraven
methylprednisolon
confer
lower
mortal
compar
group
steroid
statist
signific
among
corticosteroid
group
group
mp
group
p
oral
prednisolon
show
similar
surviv
outcom
result
interpret
caution
light
limit
retrospect
studi
without
control
group
dispar
baselin
characterist
could
secondari
select
bia
ie
choic
corticosteroid
use
dosag
might
relat
sever
ill
treatment
protocol
adopt
individu
hospit
thu
observ
steroid
type
dosag
vari
protocoldriven
lowdos
prednisolon
highdos
mp
even
puls
corticosteroid
commenc
treatment
although
corticosteroid
ribavirin
usual
given
togeth
effect
latter
like
small
predomin
corticosteroid
type
classifi
accord
use
first
four
day
subsequ
use
includ
rescu
puls
dose
total
dose
durat
administ
could
also
confound
final
conclus
believ
cytokin
storm
initi
day
sar
ill
critic
effect
manifest
diseas
appropri
level
immunomodul
stage
may
impact
subsequ
cours
ill
therefor
arbitrarili
classifi
patient
describ
also
reason
sinc
major
patient
given
corticosteroid
could
classifi
also
pao
fio
could
estim
instanc
base
assumpt
nevertheless
rule
appli
everi
patient
final
alreadi
exclud
patient
experiment
therapi
especi
antivir
like
lopinavirritonavir
may
benefici
effect
resuscit
order
still
possibl
outcom
affect
differ
mode
subsequ
manag
includ
choic
ventilatori
strategi
result
suggest
sar
patient
given
prednisolon
methylprednisolon
fare
better
given
hydrocortison
specul
may
relat
compar
higher
antiinflammatori
potenc
former
two
drug
demonstr
vitro
studi
observ
corticosteroid
dosag
employ
sar
hong
kong
divers
rang
low
dose
regimen
dosag
commonli
employ
treat
acut
asthmat
attack
higher
dosag
trigger
surrog
marker
clinic
deterior
puls
mp
dosag
treatment
acut
autoimmun
pulmonari
vascul
first
sight
appear
intrigu
lowdos
p
highdos
mp
group
result
similarli
low
mortal
rate
studi
detail
analysi
howev
appear
dosag
tailor
accord
diseas
sever
group
p
prednisolon
mildest
clinic
radiograph
paramet
receiv
lower
dosag
corticosteroid
steroid
commenc
wherea
group
mp
wors
clinic
statu
receiv
higher
initi
dosag
rel
good
outcom
mp
p
group
could
relat
lower
cumul
dose
compar
group
hc
puls
henc
modest
immunosuppress
effect
howev
must
point
group
p
mildest
diseas
throughout
hospit
stay
group
mp
much
sever
ill
henc
low
cumul
dosag
major
reason
better
outcom
two
group
specul
therefor
corticosteroid
administ
dosag
commensur
diseas
sever
may
conduc
effect
control
immunopatholog
lung
damag
addit
data
support
content
higher
corticosteroid
dosag
treatment
sar
would
necessarili
lead
infectionpron
immunocompromis
state
highdos
protocoldriven
group
mp
methylprednisolon
higher
wors
median
cxr
score
corticosteroid
commenc
display
low
mortal
rate
lowest
proportion
requir
puls
mp
rescu
also
turn
consist
lower
rate
posit
bacteri
fungal
cultur
well
antifung
treatment
high
dose
methylprednisolon
benefici
lower
dosag
corticosteroid
also
shown
compar
studi
mainland
china
two
hospit
use
specif
treatment
protocol
throughout
outbreak
appli
differ
regimen
differ
patient
differ
phase
outbreak
definit
conclus
effect
corticosteroid
difficult
even
though
adjust
baselin
differ
use
multivari
analysi
report
seri
literatur
corticosteroid
start
treat
sar
variabl
usual
much
earlier
time
point
includ
soon
diagnosi
sar
made
without
respons
antibiot
treatment
within
h
confirm
epidemiolog
link
contact
histori
find
lung
involv
highresolut
ct
thorax
alon
despit
clear
chest
radiograph
earli
corticosteroid
administr
strategi
might
led
drug
given
earli
viral
replic
phase
may
result
aggrav
andor
prolong
viral
replic
thu
less
satisfactori
outcom
therefor
submit
low
mortal
morbid
group
mp
may
result
effect
control
sever
diseas
appropri
high
dosag
corticosteroid
high
antiinflammatori
activ
given
strateg
time
per
protocol
coincid
period
high
sarsrel
immunopatholog
activ
strategi
would
allow
smooth
tail
corticosteroid
dosag
avoid
diseas
rebound
well
risk
secondari
infect
subsequ
phase
immunoparesi
contrast
group
hc
also
receiv
high
cumul
corticosteroid
dosag
high
proport
patient
requir
puls
mp
rescu
display
highest
posit
bacteri
fungal
tuberculosi
infect
postul
compar
weaker
antiinflammatori
effect
hydrocortison
group
might
result
incomplet
control
sar
thu
persist
elev
cytokin
earlier
stage
turn
may
promot
bacteri
prolifer
context
high
cumul
corticosteroid
dosag
later
stage
hospitalis
result
increas
need
rescu
dosag
could
also
contribut
excess
secondari
infect
among
patient
receiv
hydrocortison
cytokin
assay
specif
perform
purpos
studi
although
definit
answer
best
time
dosag
durat
corticosteroid
administr
obtain
largescal
randomis
placebocontrol
trial
potenti
effect
antivir
agent
supplement
corticosteroid
secondari
rescu
treatment
analys
suggest
appropri
severityadjust
corticosteroid
dosag
especi
highdos
methylprednisolon
commenc
overt
respiratori
deterior
sever
case
associ
better
outcom
manag
sever
acut
respiratori
syndrom
